Australian biotech market today 15.04.09
Wednesday, 15 April, 2009
The healthcare index was a bright spot on an otherwise poor day for listed stocks, up 0.32 per cent at 3.30pm today.
Drug delivery company Acrux (ASX:ACR) is up 7c to 70c following yesterday’s ruling that it resume mediation with its US licensee, Vivus, over beginning a Phase III trial of its testosterone spray for women, Luramist.
Alchemia (ASX:ACL) was up 3.5c to 34c while Atcor (ASX:ACG) is up a cent to 21c on today’s news that it has signed two more sales contracts for its SphygmoCor blood pressure systems, bringing total contracts in the past year to US$7.3 million.
Circadian (ASX:CIR) was down a touch, while Cellestis (ASX:CST) lost some of yesterday’s gains, settling at $2.60.
Pharmaxis (ASX:PXS) has regained some of yesterday’s losses and is back over $2.00, while Mesoblast (ASX:MSB) is up a little.
Cochlear (ASX:COH) is down almost a dollar, while CSL (ASX:CSL) is up 40c and ResMed (ASX:RMD) is up 23c.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
